We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

Long-term Treatment for Severe Psoriasis We're Halfway There, With a Long Way to Go

Joel M. Gelfand, MD, MSCE
Arch Dermatol. 2007;143(9):1191-1193. doi:10.1001/archderm.143.9.1191.
Text Size: A A A
Published online


Over the last 30 years, the landmark PUVA [psoralen–UV-A] Follow-up Study has demonstrated the importance of clinical epidemiology research in making informed treatment decisions for patients with psoriasis. When PUVA was first introduced, psoriasis was widely believed to be an epidermal cell proliferation disorder, and there were few systemic treatment options available at that time.1 Thirty years later, psoriasis is believed to be an immunologic disorder, and more new systemic therapies have been approved to treat it in the last 4 years than in the previous 30 years combined.28 Our objective criterion regarding which patients have severe psoriasis and therefore are candidates for systemic therapy has also evolved during this period, declining from 20% to 30% body surface area (BSA) in the 1970s to 1990s to 5% more recently.9,10 With the increasing recognition of the impact of psoriasis on health-related quality of life and the advent of novel therapies targeting its immunopathogenesis, the treatment of psoriasis is undergoing a revolution. As patients with psoriasis are increasingly being treated with systemic agents on a long-term basis, the PUVA study provides an important reminder of the challenge involved in making clinical decisions based on a scientific understanding of the disease's natural history and the robust long-term safety and efficacy data of its treatments.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

7 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles